Dendreon Provenge Approval Call Summary (45.50 +5.88) -Update : During the call, the co said that it will provide Provenge to 2000 patients in next 12 months. Co said that demand for Provenge will exceed co's ability to provide it in the first 12 months; will continue build out of manufacturing capabilities. Mgmt said that 1 infusion will cost $31k; complete course will cost $93k. and EPS of $1.65.
http://www.StockMarketFunding.com S&P 500 Earnings Forecast Video True Value of S&P 500 $92/Share Nope Try $55/share S&P 500 Technical Analysis 2010 Trend Analysis Professional Commentary SMF Downgraded US GDP and S&P 500 Earnings for 2011